At the news
? NEUTRALIMPACT 6/10 DEFA14A filed Nov 9, 2026 at 17:05 ET
Heron Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) announcing that CorMedix will acquire substantially all of Heron's assets, including its four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL), for upfront consideration of $145 million in cash and 14,583,333 shares of CorMedix common stock (valued at approximately $77.6 million based on CRMD's November 6, 2026 closing price of $5.32), plus potential earn-out payments of up to $55 million and royalties. The transaction is expected to close in Q1 2027, subject to Heron stockholder approval, regulatory clearance, and other customary conditions. Stockholders representing approximately 22% of Heron's outstanding common stock have agreed to vote in favor.
- CorMedix to acquire substantially all of Heron's assets for $145 million cash plus 14,583,333 shares of CorMedix common stock (aggregate upfront value approx. $222.6 million based on CRMD closing price of $5.32 on Nov 6, 2026)
- Heron eligible for up to $55 million in earn-out payments: $25 million if ZYNRELEF net sales >= $65 million in 2028, plus $30 million if ZYNRELEF net sales >= $95 million in 2028
- Heron to receive a 5% royalty on combined annual net sales above $25 million in each of years 2027-2029 of CINVANTI, SUSTOL and products under Heron's multi-product Development and License Agreement
- Hercules Capital credit facility expected to be repaid at closing from upfront cash consideration
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access